PF 4382923
Alternative Names: PF-04382923; PF4382923; RN-6GLatest Information Update: 05 Nov 2023
At a glance
- Originator Pfizer
- Class Antibodies; Eye disorder therapies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dry age-related macular degeneration
Most Recent Events
- 09 May 2013 Discontinued - Phase-II for Dry age-related macular degeneration in United Kingdom (IV)
- 09 May 2013 Discontinued - Phase-II for Dry age-related macular degeneration in USA (IV)
- 27 Mar 2013 Pfizer completes a phase I trial in Dry age-related macular degeneration in USA (NCT01003691)